Novo, J&J Alzheimer’s clinical flops teach bruised field valuable lessons

November was a tough month for highly anticipated Alzheimer’s readouts with a GLP-1 and tau-targeting drug coming up short in late-stage trials.

A drugmaker charts a path through pharma’s ethical minefields

As the science behind pharma breakthroughs becomes more complex, bioethicists are helping companies navigate moral quandaries.

Along with NIH cuts come risks to patient safety and scientific data

The abrupt withdrawal of research funds affected 74,000 clinical trial participants, including some already taking the drugs being studied.

4 takeaways from pharma’s manufacturing boom

As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.

What’s next in the eye disease pipeline?

An early gene therapy breakthrough spurred investments, but can the industry maintain momentum?  

Eli Lilly becomes first drugmaker to hit $1 trillion in market value

The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech titans like Apple and Google and dwarfed that of its drugmaking peers.

Pharma faces a critical ‘turning point’ in 2026, years in the making

While Trump’s manufacturing and pricing deals with pharma shape the industry’s future, COVID’s impact still ripples throughout the health landscape.